Hanall Biopharma Co., Ltd.

Hae-Young Yong

Eun Sun Kim

Sung Wuk Kim

Seung Kook Park

Jae Kap Jeong

Yeon Jung Song

Dongok Shin

Min Sun Kim

Hyea Kyung Ahn

Tae Hyoung Yoo

Jeong Haing Heo

The present disclosure relates to an isolated anti-FcRn antibody, which is an antibody binding to FcRn (stands for neonatal Fc receptor, also called FcRP, FcRB or Brambell receptor) that is a receptor with a high affinity for IgG or a fragment thereof, a method of preparing thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune diseases using the antibody. The FcRn-specific antibody according to the present disclosure binds to FcRn non-competitively with IgG to reduce serum pathogenic auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.

Antibody binding to FCRN for treating autoimmune diseases

Antibody binding to FcRn for treating autoimmune diseases

The present invention relates to a human antibody specific for FcRn that is a receptor with a high affinity for IgG, a production method thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune disease using the same. The FcRn-specific antibody according to the present invention can bind to FcRn non-competitively with IgG or the like to reduce serum auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.

FcRn-specific human antibody and composition for treatment of autoimmune diseases

Growing community of inventors

Gyeonggi-do, South Korea

Hae-Young Yong